id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S10174 R37213 |
Blotière (Valproate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 | Cleft lip with or without cleft palate | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
4.94 [0.82;29.59] C excluded (control group) |
3/913 2/2,997 | 5 | 913 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10051 R36487 |
Blotière (Valproate) (Controls unexposed NOS) (Mixed indications), 2019 | Cleft lip with or without cleft palate | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 3.90 [0.80;11.40] | 3/913 1,637/1,875,733 | 1,640 | 913 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9329 R32532 |
Viinikainen (Valproate) (Controls unexposed, sick) a, 2006 | Cleft lip | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 1.87 [0.04;96.99] C | 0/28 0/52 | 0 | 28 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9330 R32541 |
Artama (Valproate), 2005 | Cleft lip/ cleft palate | 1st trimester | retrospective cohort (registry) | unexposed, sick | Adjustment: No | 9.08 [1.75;47.07] C | 5/263 2/939 | 7 | 263 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 3 studies | 5.08 [1.87;13.82] | 1,647 | 1,204 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Valproate) (Controls unexposed NOS) (Mixed indications; 2: Valproate) (Controls unexposed, sick) ; 3: Valproate;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 10174